Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Challenge of Evaluating Response to Peptide Receptor Radionuclide Therapy in Gastroenteropancreatic Neuroendocrine Tumors: The Present and the Future
Virginia Liberini, Martin W. Huellner, Séréna Grimaldi, et al.
Diagnostics (2020) Vol. 10, Iss. 12, pp. 1083-1083
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Radiopharmaceutical Treatments for Cancer Therapy, Radionuclides Characteristics, Applications, and Challenges
Suliman Salih, Ajnas Alkatheeri, Wijdan Alomaim, et al.
Molecules (2022) Vol. 27, Iss. 16, pp. 5231-5231
Open Access | Times Cited: 53
Prediction of177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study
Magdalena Mileva, Gwennaëlle Marin, Hugo Levillain, et al.
Journal of Nuclear Medicine (2023) Vol. 65, Iss. 2, pp. 236-244
Open Access | Times Cited: 24
[68Ga]DOTATOC PET/CT Radiomics to Predict the Response in GEP-NETs Undergoing [177Lu]DOTATOC PRRT: The “Theragnomics” Concept
Riccardo Laudicella, Albert Comelli, Virginia Liberini, et al.
Cancers (2022) Vol. 14, Iss. 4, pp. 984-984
Open Access | Times Cited: 31
Peptide Receptor Radionuclide Therapy of Neuroendocrine Tumors: Agonist, Antagonist and Alternatives
Giulia Santo, Gianpaolo di Santo, Irene Virgolini
Seminars in Nuclear Medicine (2024) Vol. 54, Iss. 4, pp. 557-569
Open Access | Times Cited: 6
Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy of177Lu-DOTATATE in Neuroendocrine Tumors
Lisa Bodei, Nitya Raj, Richard Kinh Gian, et al.
Journal of Nuclear Medicine (2022) Vol. 64, Iss. 4, pp. 567-573
Open Access | Times Cited: 22
Diagnosis, Management and Theragnostic Approach of Gastro-Entero-Pancreatic Neuroendocrine Neoplasms
Leandra Piscopo, Emilia Zampella, Sara Pellegrino, et al.
Cancers (2023) Vol. 15, Iss. 13, pp. 3483-3483
Open Access | Times Cited: 11
Automated liver lesion detection in 68Ga DOTATATE PET/CT using a deep fully convolutional neural network
Jonathan Wehrend, Michael Silosky, Fuyong Xing, et al.
EJNMMI Research (2021) Vol. 11, Iss. 1
Open Access | Times Cited: 26
The South Australian 177Lu-DOTATATE peptide receptor radionuclide therapy service: an 11-year review of toxicity, health-related quality of life, and survival
L.M. Altus, Jake C. Forster, Jean-Pierre Di Mercurio, et al.
ESMO Gastrointestinal Oncology (2025) Vol. 8, pp. 100146-100146
Closed Access
Relationship Between Best Tumor Shrinkage and Progression‐Free Survival and Overall Survival in Patients With Progressive Midgut Neuroendocrine Tumors Treated With [177Lu]Lu‐DOTA‐TATE: Ad Hoc Analysis of the Phase III NETTER‐1 Trial
Marianne Pavel, Martyn Caplin, Philippe Ruszniewski, et al.
Cancer Medicine (2025) Vol. 14, Iss. 9
Open Access
Emerging innovations in theranostics for pancreatic neuroendocrine tumors
Anita Karimi, Christina Bogdani, Elisabeth O’Dwyer, et al.
npj Precision Oncology (2025) Vol. 9, Iss. 1
Open Access
Prognostic Value of Whole-Body PET Volumetric Parameters Extracted from 68Ga-DOTATOC PET/CT in Well-Differentiated Neuroendocrine Tumors
Philippe Thuillier, Virginia Liberini, Séréna Grimaldi, et al.
Journal of Nuclear Medicine (2021) Vol. 63, Iss. 7, pp. 1014-1020
Open Access | Times Cited: 22
Potential value of pre- and post-therapy [68Ga]Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors
Marta Opalińska, Karolina Morawiec-Sławek, Adrian Kania-Kuc, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 15
The Role of Theragnostics in Breast Cancer: A Systematic Review of the Last 12 Years
Michele Balma, Virginia Liberini, Ambra Buschiazzo, et al.
Current Medical Imaging Formerly Current Medical Imaging Reviews (2023) Vol. 19, Iss. 8
Closed Access | Times Cited: 9
Imaging and liquid biopsy in the prediction and evaluation of response to PRRT in neuroendocrine tumors: implications for patient management
Wolfgang Roll, Matthias Weckesser, Robert Seifert, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2021) Vol. 48, Iss. 12, pp. 4016-4027
Open Access | Times Cited: 19
Glucose Metabolism Modification Induced by Radioligand Therapy with [177Lu]Lu/[90Y]Y-DOTATOC in Advanced Neuroendocrine Neoplasms: A Prospective Pilot Study within FENET-2016 Trial
Luca Urso, Stefano Panareo, Angelo Castello, et al.
Pharmaceutics (2022) Vol. 14, Iss. 10, pp. 2009-2009
Open Access | Times Cited: 13
Same-day comparative protocol PET/CT-PET/MRI [68 Ga]Ga-DOTA-TOC in paragangliomas and pheochromocytomas: an approach to personalized medicine
S. Prado-Wohlwend, M. Ballesta-Moratalla, I. Torres-Espallardó, et al.
Cancer Imaging (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 6
Applications of Artificial Intelligence and Radiomics in Molecular Hybrid Imaging and Theragnostics for Neuro-Endocrine Neoplasms (NENs)
Michele Balma, Riccardo Laudicella, E. Gallio, et al.
Life (2023) Vol. 13, Iss. 8, pp. 1647-1647
Open Access | Times Cited: 4
Radio theranostics in paragangliomas and pheochromocytomas
Stefan Prado Wohlwend, Pilar Bello Arques
Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) (2024) Vol. 43, Iss. 4, pp. 500017-500017
Closed Access | Times Cited: 1
Combination of [177Lu]Lu-DOTA-TATE Targeted Radionuclide Therapy and Photothermal Therapy as a Promising Approach for Cancer Treatment: In Vivo Studies in a Human Xenograft Mouse Model
Marina Simón, Jesper Tranekjær Jørgensen, Harshvardhan A. Khare, et al.
Pharmaceutics (2022) Vol. 14, Iss. 6, pp. 1284-1284
Open Access | Times Cited: 6
Artificial Intelligence in Oncological Hybrid Imaging
Benedikt Feuerecker, Maurice M. Heimer, Thomas Geyer, et al.
RöFo - Fortschritte auf dem Gebiet der Röntgenstrahlen und der bildgebenden Verfahren (2022) Vol. 195, Iss. 02, pp. 105-114
Open Access | Times Cited: 6
Safety and Efficacy of Peptide-Receptor Radionuclide Therapy in Elderly Neuroendocrine Tumor Patients
Deborah Theiler, Marco Cattaneo, Lawrence Dierickx, et al.
Cancers (2021) Vol. 13, Iss. 24, pp. 6290-6290
Open Access | Times Cited: 7
Know thy tumour: Biomarkers to improve treatment of molecular radionuclide therapy
Edward O’Neill, Bart Cornelissen
Nuclear Medicine and Biology (2022) Vol. 108-109, pp. 44-53
Open Access | Times Cited: 3
Challenges in Von Hippel–Lindau’s disease: PRRT in patients on hemodialysis
Nazia Ayub, Arthur J. A. T. Braat, Henri Timmers, et al.
Endocrinology Diabetes and Metabolism Case Reports (2022) Vol. 2022
Open Access | Times Cited: 3
The prognostic role of whole-body volumetric 68GA-DOTATATE PET/computed tomography parameters in patients with gastroenteropancreatic neuroendocrine tumor treated with 177LU-DOTATATE
Ferat Kepenek, Halil Kömek, Canan Can, et al.
Nuclear Medicine Communications (2023) Vol. 44, Iss. 6, pp. 509-517
Closed Access | Times Cited: 1
Artificial Intelligence and Radiomics Applications in Neuro-endocrine Neoplasms (NENs): New Tools for Molecular Hybrid Imaging and Theragnostics Approaches
Michele Balma, Riccardo Laudicella, E. Gallio, et al.
(2023)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top